A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201)
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Sotorasib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CodeBreaK 201
- Sponsors Amgen
- 12 Dec 2023 This trial has been discontinued in Sweden, according to European Clinical Trials Database record.
- 25 Oct 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 10 Oct 2023 Planned End Date changed from 23 Aug 2024 to 14 Nov 2024.